NCT05448443View on ClinicalTrials.gov

Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

May 8, 2024

Study Completion Date

May 8, 2024

Conditions
Obesity Hypoventilation Syndrome (OHS)
Interventions
DRUG

AD981

Oral administration of AD981 in the morning and before sleep for 14 days

OTHER

Placebo

Oral administration of placebo in the morning and before sleep for 14 days

Trial Locations (1)

Unknown

Istituto Auxologico Italiano,Ospedale San Luca, Milan

Sponsors

Collaborators (1)

Apnimed Inc.
All Listed Sponsors
collaborator

Apnimed Inc.

UNKNOWN

collaborator

VIS Ethic Research Srl

UNKNOWN

collaborator

University of Florence

OTHER

collaborator

STM Pharma PRO srl

UNKNOWN

lead

Istituto Auxologico Italiano

OTHER